Moxifloxacin is a fourth-generation fluoroquinolone antibacterial that inhibits bacterial DNA gyrase and topoisomerase IV. It offers enhanced activity against Gram-positive organisms including Streptococcus pneumoniae, along with broad coverage of Gram-negatives, atypicals, and anaerobes. Indicated for community-acquired pneumonia, acute bacterial exacerbation of chronic bronchitis, acute bacterial sinusitis, complicated skin and skin-structure infections, and complicated intra-abdominal infections in adult patients.